Neurotech International Ltd. has released a press release.
NTI secures Notices of Allowance for US patent applications
Earlier from Neurotech International
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- Appendix 4D & Half Year Report
- Positive 90-day GLP toxicology study results in non-rodents
- Approval received for NTI164 Phase 3 Clinical Study in ASD